Prevention of critical telomere shortening by oestradiol in human normal hepatic cultured cells and carbon tetrachloride induced rat liver fibrosis

R Sato, C Maesawa, K Fujisawa, K Wada, K Oikawa, Y Takikawa, K Suzuki, H Oikawa, K Ishikawa, T Masuda

Background and aim: Significant telomere shortening of hepatocytes is associated with replicative senescence and a non-dividing state in chronic liver disease, resulting in end stage liver failure and/or development of hepatocellular carcinoma. To prevent critical telomere shortening in hepatocytes, we have focused on oestrogen dependent transactivation of the human telomerase reverse transcriptase (hTERT) gene as a form of telomerase therapy in chronic liver disease.

Methods: We examined expression of hTERT mRNA and its protein, and telomerase activity (TA) in three human normal hepatic cell lines (Hc-cells, h-Nheps, and WRL-68) before and after treatment with 17β-oestradiol. The effects of exogenous oestriadiol administration were examined in a carbon tetrachloride (CCL4) induced model of liver fibrosis in rats.

Results: Expression of hTERT mRNA and its protein was upregulated by oestradiol treatment. Telomere length decreased in Hc-cells and h-Nheps with accumulated passages whereas with long term oestradiol exposure it was greater than without oestradiol. The incidence of β-galactosidase positive cells, indicating a state of senescence, decreased significantly in oestradiol treated cells in comparison with non-treated cells (p<0.05). TA in both male and female rats with CCL4 induced liver fibrosis was significantly higher with oestradiol administration than without (p<0.05). Long term oestradiol administration markedly rescued the hepatic telomere from extensive shortening in both male and female rats.

Conclusion: These results suggest that oestradiol acts as a positive modulator of the hTERT gene in the liver. Oestrogen dependent transactivation of the hTERT gene is a new strategy for slowing the progression of chronic liver disease.

Progression of chronic liver disease that culminates in cirrhosis is characterised by chronic hepatocyte death and renewal over a period of years. In the process, abnormal patterns of hepatocyte regeneration and fibrous scarring are promoted, and these architectural abnormalities accelerate to compromise hepatocyte function, causing systemic life threatening complications. The liver tries to compensate for the dysfunction by producing new hepatocytes. However, the hepatocytes eventually stop cell division, and this in turn results in end stage organ failure. To attempt a new treatment strategy for slowing the progression of chronic liver disease, several researchers have extensively studied the mechanism of fibrotic or cirrhotic initiation and progression at the level of cellular and molecular events. Two major hypotheses have been proposed for the molecular mechanism governing the progressive induction of cirrhosis during its long latency. One is that hepatic stellate cells (HSCs) are responsible for hepatofibrogenesis. With the stimulation of inflammation, toxification, and activation signals released from the destroyed hepatocytes themselves, HSCs are converted to myofibroblast-like cells. Activated HSCs secrete extracellular matrix components and fibrosis implementing factors, such as transforming growth factor β1 (TGF-β1) and platelet derived growth factor. These cellular and molecular mechanisms presumably contribute to initiation and/or progression of hepatic fibrosis.

As the second key aspect of terminal liver failure, hepatocyte proliferative arrest has been linked to several actiological factors, including altered hepatocyte-matrix interactions, growth inhibition by abundant TGF-β1 and/or critical telomere shortening.

The telomere is a special cap-like structure at the end of eukaryotic chromosomes, composed of a tandem repeat of TTAGGG. Continuous shortening of the telomere occurs during each cell division, due to an end replication problem. Significant telomere shortening is associated with replicative senescence and a non-dividing state, the “Hayflic limit/ mortality stage 1 (M1)”, through activation of the pRb and p53 pathway. More continuous telomere shortening beyond the Hayflic limit leads to loss of telomere capping activity, culminating in severe chromosomal instability and massive cell death, referred to as “crisis/mortality stage 2 (M2)”. The telomere hypothesis proposes that chronic liver injury induces continuous cell death and regeneration, resulting in critical telomere shortening, which in turn culminates in hepatocyte replicative senescence or crisis (fig 1A). Some researchers have discovered that hepatocytes in liver cirrhosis have shorter telomeres than those from age matched healthy hepatocytes. Moreover, quantitative results for telomere length were well correlated with senescence associated β-galactosidase staining, a biomarker for senescence, in hepatocytes of humans with cirrhosis.

Abbreviations: HSC, hepatic stellate cells; TGF-β1, transforming growth factor-β1; M1, mortality stage 1; M2, mortality stage 2; OR, oestrogen receptor; TA, telomerase activity; TRF, terminal restriction fragment; RQ-PCR, real time quantitative-polymerase chain reaction; TRE assay, telomeric repeat elongation assay; e value, elongation value; CCL4, carbon tetrachloride; SDS, sodium dodecyl sulphate; RU, resonance unit; PBS, phosphate buffered saline.
dependent transactivation of the hTERT gene is carried out by direct interaction of activated oestrogen receptor (OR) with an imperfect oestrogen response element in the hTERT promoter. Exogenous oestriadiol administration may not only help to suppress induction of hepatic fibrosis by HSCs but also prevent critical telomere shorting of hepatocytes by transactivation of the hTERT gene (fig 1B). The present study examined the effects of oestradiol on telomerase activity (TA) and telomere length in human normal hepatic cultured cells and a carbon tetrachloride (CCl4) induced liver cirrhosis model in rats.

MATERIALS AND METHODS
Cell culture
One hepatocellular carcinoma cell line, Hep 3B (Cell Resource Centre for Biomedical Research, Tohoku University, Sendai, Japan) and three human normal hepatocyte cell lines, Hc-cells (Applied Cell Biology Research Institute, Human Hepatocyte Cell culture #3716, Kirkland, Washington, USA), h-Nheps (BioWhittaker, Walkersville, Maryland, USA), and WRL-68 (American Type Culture Collection, Rockville, Maryland, USA) were obtained commercially. They were maintained under the recommended conditions. For the oestradiol induction assay, they were cultured in phenol red-free medium (RPMI-1640; Invitrogen, Grand Island, New York, USA) supplemented with 10% charcoal/dextran treated fetal bovine serum (HyClone Laboratories Inc., Logan, Utah, USA).

For the evaluation of telomerase activity (TA), cells were seeded at 1 x 10^5 cells per 100 mm petri dish, and subsequently cultured in the above mentioned medium without oestradiol. After 24 hours of incubation, the medium was replaced with that containing 1, 10, or 100 nM 17b-oestradiol (oestradiol: 1.3.5(10)-estratriene-3, 17b-diol; Sigma, St Louis, Missouri, USA). Telomerase was extracted after 48 hours of exposure to oestradiol.

For determination of terminal restriction fragment (TRF) length, all cells were continuously exposed to oestradiol (10 nM) or untreated. We started a long term culture with continuous oestradiol exposure after three passages from the time when cells were purchased. Cells were passaged weekly at 75% confluence using 0.25% trypsin/0.02% ethylenediaminetetraacetic acid (Invitrogen) for detachment and seeding of new dishes using a split ratio of 1:10. DNAs of cells were extracted at the 10th, 20th, and 30th passages.

Preparation of animals
Forty Fisher rats—20 males and 20 females—(CLEA Japan Inc, Tokyo, Japan) at five weeks old, weighing 102 (13) g, were used. They were divided into two groups: CCl4 alone (group A) and CCl4+oestradiol (group B). Twenty rats—10 males and 10 females—were prepared as a non-treatment control. All rats were injected intramuscularly with 10% CCl4 in olive oil at a dose of 1 ml/kg body weight twice weekly. Rats in group B additionally received an intraperitoneal injection of oestradiol (1.3.5(10)-estratriene-3, 17b-diol 17-pentanoate; Mochida Pharmaceutical Co., Tokyo, Japan) in olive oil at a dose of 3.3 mg/kg body weight twice weekly. All animals were anaesthetised with sodium pentobarbital (40 mg/kg body weight intraperitoneally) and killed by terminal exsanguination from the inferior vena cava at 24 and 48 weeks. Japanese national guidelines for the care of animals were followed.

Western blot analysis
Cell lines and rat liver tissues were dissolved in cell lysis buffer (50 mM HEPES (pH 7.5)/1 mM EDTA/150 mM NaCl/2.5 mM EGTA/1.0% NP-40) and the clear supernatants were collected after a 30 minute rotation. Protein concentration in
the lysates was determined spectrophotometrically using an RC DC Protein Assay Kit (Bio-Rad, Hercules, California, USA), and 5 μg of extract was subjected to sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis. Proteins were transferred to Hybond-P membranes (Amersham Biosciences, Buckinghamshire, UK). A primary polyclonal antibody against ORx (MC-20; Santa Cruz Biotechnology, Santa Cruz, California, USA; diluted 1:5000) or a monoclonal antihuman TERT antibody (NCL-TERT; Novocastra Laboratories Ltd, Newcastle upon Tyne, UK) was applied to the membrane for 60 minutes at room temperature. The secondary antibody, antirabbit IgG or antimeouse IgG (Amersham Biosciences) diluted 1:10 000 in blocking buffer, was applied for 45 minutes at room temperature. Both expressions were detected by an ECL (enhanced chemiluminescence) Western Blotting Detection System Kit (Amersham Biosciences).

**Telomerase assays**

TA was measured by the modified telomeric repeat elongation assay (TRE) assay, which is a rapid and sensitive direct telomerase assay that has many advantages over conventional polymerase chain reaction (PCR) based methods. The most significant advantage is that the TA of somatic cells or tissues can be evaluated quantitatively, eliminating inhibitors of DNA polymerase in the reaction mixture. The 5′-biotinylated oligomers (TS-5′B: biotin-5′-AAT CCG TCG AGC AGA GTT AGG GTT AGG GTT AGG GTT AG –3′) were immobilised on streptavidin pretreated dextran sensor surfaces in situ using a Biacore apparatus (Biacore 3000; Biacore AB, Uppsala, Sweden). In the modified TRE assay, we also immobilised identical oligomers that were biotinylated at the 3′ end (TS-3′B) on a reference flow cell. The modification achieved more precise quantification of telomerase activity. Conditions and reaction buffers have been described previously. Briefly, cell extracts containing telomerase were extracted by the conventional method and diluted in TRE buffer (10 mM HEPES, pH 7.4/150 mM NaCl/10 mM MgCl2/2.5 mM dNTP/10 mM EGTA) to 0.1 mg/ml. They were applied at 5 μl/min across the chip surface for five minutes at 37°C. The chip surface was regenerated by washing with a 100 μl pulse of 1% SDS in 10 mM HEPES, which removed all proteins, at a flow rate of 100 μl/min. After regeneration, the flow rate returned to 5 μl/min. We defined the elongation value (e value) as the difference in resonance unit (RU) between baseline levels before the extract injection and after the regeneration phase. All values were determined from 3–6 independent assays, and the coefficients of variation of all values were determined from 3–6 replicate measurements ranging from 5 pg to 0.005 fg (2×106 to 2 copies). For normalisation, the copy number of GAPDH was used as an internal control.

Five independent assays were performed on each RNA sample extracted from hepatocyte cell lines. For analysis in the animal model of CCL4 induced liver fibrosis, we performed five independent assays, and calculated mean normalised copy number for each rat.

**TRF length analysis**

DNA was isolated and then digested with the restriction enzyme Hinfl. DNA (10 μg/lane) was loaded onto a 0.8% agarose gel and electrophoresed for 12–20 hours at 60 V. The gel was denatured in 0.5 M NaCl and 0.5 M NaOH for 40 minutes, and neutralised in 1.5 M NaCl and 1 M Tris HCl (pH 7.5) for 40 minutes. Then, DNA was transferred onto Hybond-N membrane (Amersham Biosciences) in 20×SSC for two hours using a VactiGene-XL blotting apparatus (Amersham Biosciences). The membrane was hybridised to a 5′-[32P]-(TTAGGG)4 probe in Perfect Hyb plus hybridisation buffer (Sigma) at 42°C for 12 hours, then finally give two washes in 0.1% SDS, 1×SSC at 42°C, prior to exposure to Kodak XAR film (Kodak, Tokyo, Japan) at −80°C for 1–2 days. Each lane was scanned with a densitometer and mean TRF length was calculated.

**Senescence associated β-galactosidase staining**

Senescence associated β-galactosidase staining was performed as described previously. In brief, cells were fixed...
Table 1 Results of real time quantitative-polymerase chain reaction assay for measuring hTERT mRNA in human normal hepatic cell lines

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Oestradiol (−)</th>
<th>Oestradiol (+)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hc-cells</td>
<td>10.9 (4.23)</td>
<td>115 (22.3)*</td>
</tr>
<tr>
<td>WRL-68</td>
<td>468 (42.0)</td>
<td>767 (130)*</td>
</tr>
<tr>
<td>h-Nheps</td>
<td>0</td>
<td>8.06 (4.44)*</td>
</tr>
</tbody>
</table>

Values are means (SD) of five independent assays. *Final concentration of oestradiol in the supernatant was 10 nM. p<0.05 by analysis of variance.

Results of real time quantitative-polymerase chain reaction assay for measuring hTERT mRNA in human normal hepatic cell lines

Expression of ORα and hTERT in human normal hepatic cell lines

Oestradiol induction assay on hTERT expression and telomerase activity in human normal hepatic cell lines

Statistical analysis

For comparison of the e value of rat liver tissues measured by TRE assay among controls, group A, and group B, analysis of variance (ANOVA) was performed followed by the least significant difference method. For comparison of the number of senescent cells between oestradiol and non-oestradiol treated cell lines, the Mann-Whitney U test was used. ANOVA was used for the remaining statistical analyses of differences between oestradiol treated and non-oestradiol treated cell lines and animals, using a significance level of p<0.05.

RESULTS

Expression of ORα and hTERT in human normal hepatic cell lines

All human normal hepatic cell lines (Hc-cells, h-Nheps, and WRL-68) expressed ORα to various degrees (fig 2A). Overexpression of hTERT protein was observed in WRL-68 (fig 2B). WRL-68 had been established from a fetal liver and is well known as a telomerase positive cell line. Hc-cells were weakly positive and h-Nheps was negative for hTERT protein (fig 2B). Quantitative results for hTERT mRNA measured by RQ-PCR assay were compatible with the results of western blotting (table 1).

Oestradiol induction assay on hTERT expression and telomerase activity in human normal hepatic cell lines

In all human normal hepatic cell lines, a concentration dependent increase in hTERT protein expression by oestradiol induction was observed (fig 3) although this was weaker in h-Nheps than in the two other cell lines (Hc-cells and WRL-67) (fig 3C). Quantitative results for hTERT mRNA measured by RQ-PCR assay were compatible with the results of western blotting (table 1). TAs of Hc-cells and h-Nheps were significantly increased after treatment with oestradiol (p<0.05) whereas that of WRL-68 was slightly increased. However, the difference was not significant (table 2, fig 4A, 4B). Increased TAs of three normal hepatic cell lines on oestradiol induction, ranging from 35.2 to 88.2 RU, were, however, relatively low in comparison with that of a hepatocellular carcinoma cell line (Hep 3B; e-value 118 RU).

TRF length and senescence associated β-galactosidase staining assays in human normal hepatic cell lines on long term exposure to oestradiol

Two cell lines (Hc-cells and h-Nheps) exhibiting activation of TA by oestradiol induction were long term cultured with or without oestradiol exposure, and TRF length and senescence associated β-galactosidase staining assays were performed.

---

For the full text, please refer to the original source at [www.gutjnl.com](http://www.gutjnl.com).
Effects of oestradiol in the CCl₄ induced cirrhosis model in the rat liver

Control livers showed only slight collagen deposition limited to the area around the central veins. Both the CCl₄ alone (group A) and CCl₄+oestradiol (group B) groups exhibited extensive fibrosis (P-P and P-C bridging fibrosis), infiltration of inflammatory cells, and necrosis of hepatocytes at 24 and 48 weeks. Fibrosis and architectural alterations were greater in group A livers than in group B livers (fig 8). Quantitative assessments of fibrotic areas showed significant differences between group A and group B at 24 and 48 weeks (p<0.05) (fig 9A). The degree of hepatic fibrosis was more accelerated at 48 weeks than at 24 weeks. There was no significant difference in the Ki67 labelling index between the two groups (fig 9B).

In order to evaluate TA and TRF lengths, telomerase extracts and DNA were obtained from liver tissues at 24 and 48 weeks. TAs of non-treated controls and group A were extremely low, and there were no significant differences between male and female rats or between control and group A rats (table 4). TAs were significantly increased in both male and female rats of group B compared with those in Group A or in non-treated control rats (table 4, fig 4C). E values in group B were slightly greater in female than in male rats but not to a significant extent (table 4, fig 4C).

TRF length analysis demonstrated loss of telomeric DNA in CCl₄ induced liver fibrosis. Although mean TRFs of normal rat liver were long (>20 kb), as described previously, extensive shortening of telomere length and a decrease in the total amount of telomeric DNA were observed as the period of CCl₄ treatment was prolonged. In addition, fragments shorter than 1 kb were markedly increased in CCl₄ treated rats. The source of the shorter telomeric DNA fragments (1 kb) may have been hepatocytes rendered apoptotic or necrotic by CCl₄ injury. We could not evaluate mean TRF length in CCl₄ induced liver fibrosis because of an abundance of shorter telomeric DNA fragments. However, the longest length of telomeric DNA was greater in female rats in group B than in those in group A at both 24 and 48 weeks (fig 10). In male rats, a difference in TRF lengths

WRL-68 appeared to be immortalised, judging from its telomerase activity, and therefore it was eliminated from the examination of long term oestradiol exposure. Telomere shortening was observed in both cell lines (table 3, fig 5). TRF lengths decreased with accumulated passages whereas those of oestradiol treated cells were greater than those without oestradiol exposure (fig 5). The incidence of β-galactosidase positive cells increased with accumulated passages, and was significantly decreased in oestradiol treated cells in comparison with non-treated cells at the same number of passages (figs 6, 7).

Table 2  Elongation values (e values) of human normal hepatic cell lines measured by the telomeric repeat elongation assay

<table>
<thead>
<tr>
<th>Cell lines</th>
<th>Oestradiol (--o)</th>
<th>Oestradiol (++)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hc-cells</td>
<td>9.5 (4.3)</td>
<td>47.0 (8.2)*</td>
</tr>
<tr>
<td>WRL-68</td>
<td>31.3 (6.0)</td>
<td>35.2 (5.5)</td>
</tr>
<tr>
<td>h-Nheps</td>
<td>8.1 (3.5)</td>
<td>88.2 (7.1)*</td>
</tr>
</tbody>
</table>

Values are means (SD) of five independent assays. *Final concentration of oestradiol in the supernatant was 10 nM.

Table 3  Mean terminal restriction fragment (TRF) length, evaluated by Southern blot analysis

<table>
<thead>
<tr>
<th>Cell lines</th>
<th>Mean TRF length (kb)</th>
<th>Oestradiol (--o)</th>
<th>Oestradiol (++)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hc-cells</td>
<td>10th</td>
<td>4.7 (1.8)</td>
<td>6.5 (1.2)</td>
</tr>
<tr>
<td></td>
<td>20th</td>
<td>3.2 (0.8)</td>
<td>3.9 (0.6)</td>
</tr>
<tr>
<td></td>
<td>30th</td>
<td>2.6 (0.2)</td>
<td>3.1 (0.4)</td>
</tr>
<tr>
<td>h-Nheps</td>
<td>10th</td>
<td>5.0 (1.4)</td>
<td>6.7 (1.1)</td>
</tr>
<tr>
<td></td>
<td>20th</td>
<td>3.3 (0.6)</td>
<td>4.2 (0.8)</td>
</tr>
<tr>
<td></td>
<td>30th</td>
<td>3.0 (0.4)</td>
<td>3.1 (0.5)</td>
</tr>
</tbody>
</table>

Values are mean (SD) for 5 rats. †Final concentration of oestradiol in the supernatant was 10 nM.
between group A and group B was confirmed at 24 weeks but was not obvious at 48 weeks. TRF lengths in female rats were greater than those in male rats.

**DISCUSSION**

The present study suggested that administration of exogenous oestradiol could rescue hepatocytes from extensive telomere shortening by upregulation of TA, resulting in prolongation of their life span, in vitro and in vivo.

Several studies have shown that most somatic cells, including hepatocytes, do not express TA, except for restricted cell types. Only endometrial tissue exhibits a menstrual phase dependent regulation of TA; upregulation of TA is observed during the proliferative phase (high oestradiol phase) but inhibited during the midsecretory phase (low oestradiol phase). Our experimental data obtained from both normal rat liver and CCl4 induced liver fibrosis failed to exhibit a significant sex related difference in TA although female rats had longer telomeres than male rats. A recent report by Cherif and colleagues has demonstrated age and sex related changes in telomere length in rats. The percentage of short telomeres increased with age in the liver and other organs of both male and female rats, and moreover males had shorter telomeres than females at the age of puberty. Identical sex related differences in telomere length have been reported in mouse liver, kidney, and spleen, and human mononuclear cells. These data strongly support the hypothesis that endogenous oestradiol may control hepatocyte TA and telomere length, and contribute to prolonging the lifespan of these cells.

**Figure 5** Terminal restriction fragments (TRF) in Hc-cells with or without long term oestradiol (E2) exposure by Southern blot analysis. An oligonucleotide probe (TTAGGG)4 was used. TRF lengths decreased with accumulated passages whereas oestradiol treated cells had longer telomeres than those without oestradiol exposure after the same number of passages. The sizes (kb) and positions of the markers are indicated on the left.

**Figure 6** Senescence associated β-galactosidase staining in h-Nheps with (B) and without (A) long term oestradiol exposure. Cells staining positively for senescence associated β-galactosidase showed dark granules in the cytoplasm. Positivity was frequently observed in non-oestradiol exposed cells.

**Figure 7** Incidence of positivity for β-galactosidase in human normal hepatic cells (Hc-cells and h-Nheps). The number of β-galactosidase positive cells increased with accumulated passages, and was significantly decreased in oestradiol (E2) treated cells in comparison with non-treated cells after the same number of passages (*p<0.05). Two researchers microscopically evaluated 500 cells five times, and determined the percentage of those staining positive for β-galactosidase.
Epidemiological data have long suggested that chronic liver disease progresses at unequal rates in the two sexes for viral hepatitis. Among patients with cirrhosis and hepatocellular carcinoma, the male:female ratio is within the range 2.3:1 to 2.6:1. Moreover, recent studies have suggested that elevated serum testosterone levels and an imbalanced testosterone/oestradiol rate are associated with an increased risk of hepatocellular carcinoma. Although the association was clearcut, the mechanism by which elevated levels of testosterone determine an increased incidence of hepatocellular carcinoma has been elusive.

It has been reported that both hormonal systems depending on testosterone and oestradiol are able to control TA, both in vitro and in vivo. Testosterone is a negative regulator of TA. Meeker and colleagues demonstrated that TA is activated in the prostate and seminal vesicles of castrated male rats. hTERT is upregulated by direct interaction with activated OR. Although the molecular mechanisms of the action of oestradiol have been well studied in HSC, those on hepatocytes have been unclear even though they have high affinity, low capacity, saturable, and specific OR. Our experimental data concerning the relationship between TA/telomere length and exogenous oestradiol administration have provided new insight into the progression of liver fibrosis and development of hepatocellular carcinoma. Continuous hepatocyte death and regeneration resulting in critical telomere shortening produce severe chromosomal instability, leading to massive cell death—so-called “crisis”. Severe chromosomal instability may play an important role in the development of hepatocellular carcinoma. Endogenous oestradiol may affect TA and the telomere length of hepatocytes, and may explain the relatively low incidence of hepatocellular carcinoma and end stage liver failure in female patients with chronic liver disease. Exogenous oestradiol administration appears to be a new treatment strategy that can be used as telomerase therapy for slowing the progression of chronic liver disease.

The telomerase gene therapy proposed by Depinho and colleagues is a fascinating option for restoring telomere length in patients with end stage liver failure. However, gene therapy using human telomerase RNA (human telomerase RNA component: hTERC) has a few limitations that need to be overcome before actual clinical application. As the hTERC gene is not deficient in human hepatocytes, it remains obscure whether hTERC gene delivery by adenovirus vectors would be able to increase telomerase activity and prevent critical telomere shortening in human hepatocytes as well as in hTERC deficient mice. In addition, considering the safety of vectors and the risk of cancer development by uncontrolled upregulation of TA, gene therapy would only be justified in patients with end stage liver failure (senescence or pre-crisis). However, the ideal telomerase therapy would be one that achieves early telomerase reactivation long before cirrhosis, thus preventing telomere dysfunction and genetic instability and reducing the rate of hepatocellular carcinoma development. For early start and long term telomerase therapy in patients with chronic liver disease, exogenous oestradiol administration is a more suitable therapeutic option than gene therapy. In the present study, we did not evaluate telomere related factors in HSCs that play an important role in hepatic fibrosis. Recent publications by Schnabl and colleagues suggested that exogenous hTERT expression resulting from retrovirus infection has a positive effect on hepatic fibrosis of HSCs. This was contradictory to our result suggesting that exogenous oestradiol administration would be helpful for preventing hepatic fibrosis. However, their experimental results using immortal HSCs infected with retrovirus were not simply compared with those of oestradiol administration. In fact, the effects of oestradiol administration in vitro and in vivo had already been
The latter studies demonstrated that the HSC phenotype was changed from activated status to quiescent status by oestradiol administration. Oestradiol exerts many actions through direct or indirect signalling pathways, and we believe that some of these may contribute to down-regulation of molecules related to hepatic fibrosis. Long term exposure to oestradiol is one of the risk factors for the development of hepatocellular carcinoma. We did not evaluate serum oestradiol levels in rats with CCl₄ induced liver fibrosis. The dose of oestradiol we used was the same as that in a previous study in which exogenous oestradiol administration suppressed fibrosis in rats with dimethyl-nitrosamine induced liver cirrhosis. In that study, serum oestradiol levels were at least 200-fold higher than those in normal non-gestational rats. Such a high level of oestradiol may be crucial from the viewpoint of hepatocyte proliferation and free radical mediated DNA/RNA damage, as described previously. However, a hyperoestrogenic state (more evident in males, known as feminisation) is frequently observed in patients with chronic liver disease without hepatocellular carcinoma. In addition, an increased testosterone/oestradiol ratio is a risk factor for hepatocellular carcinoma development whereas an increased serum oestradiol level is not in itself an independent risk factor. The contribution of a high oestradiol level to hepatocellular carcinoma development thus remains debatable.

Table 4 Elongation values (e values) of rat liver tissues measured by telomeric repeat elongation assay

<table>
<thead>
<tr>
<th>Rat liver</th>
<th>Control</th>
<th>Group A</th>
<th>Group B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>24 weeks</td>
<td>2.8 (2.2)</td>
<td>3.2 (1.5)</td>
</tr>
<tr>
<td></td>
<td>48 weeks</td>
<td>3.0 (2.0)</td>
<td>3.8 (2.4)</td>
</tr>
<tr>
<td>Female</td>
<td>24 weeks</td>
<td>1.6 (1.2)</td>
<td>6.1 (3.3)</td>
</tr>
<tr>
<td></td>
<td>48 weeks</td>
<td>3.5 (2.9)</td>
<td>7.4 (3.5)</td>
</tr>
</tbody>
</table>

Values are mean (SD) for five rats. We performed the TRE assay five times and calculated the mean e value for each rat.

*<p,<0.05 compared with the control or group A.

Figure 9 Quantitative assessments of liver fibrosis (A) and Ki67 labelling (B) in rat liver with carbon tetrachloride (CCl₄) induced cirrhosis with or without oestradiol (E₂) administration. Fibrotic areas were significantly decreased in oestradiol treated cells in comparison with those without oestradiol administration (p,<0.05). No significant difference in the Ki67 labelling index was observed between groups with and without oestradiol administration.

Figure 10 Terminal restriction fragments in rats with carbon tetrachloride (CCl₄) induced liver fibrosis with and without oestradiol (E₂) administration revealed by Southern blot analysis. Extensive telomere shortening and loss of total telomeric DNA were observed as the period of CCl₄ treatment was prolonged. In addition, fragments shorter than 1 kb were markedly increased in CCl₄ treated rats. The longest position of the telomeric DNA was greater in male and female rats administered oestradiol than in those without oestradiol at 24 weeks. Results in female rats with and without oestradiol administration were confirmed to be identical at 48 weeks but this was not evident in male rats at the same time point.
Further studies are required to determine whether a lower dose of exogenous oestradiol activates TA of hepatocytes in patients with chronic liver disease and helps rescue them from critical telomere shortening. We now intend to examine serum oestradiol levels, OR expression, TA, and telomere length in humans with chronic liver disease.

ACKNOWLEDGEMENTS

The authors wish to thank Associate Professor Kei Takahashi, Division of Mathematics, Iwate Medical University School of Liberal Arts and Sciences, for statistical analyses. The work was supported in part by a grant from Keiyokai Research Foundation 2001-2002, and grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (No 14570136 and 15591432).

References

Prevention of critical telomere shortening by oestradiol in human normal hepatic cultured cells and carbon tetrachloride induced rat liver fibrosis

R Sato, C Maesawa, K Fujisawa, K Wada, K Oikawa, Y Takikawa, K Suzuki, H Oikawa, K Ishikawa and T Masuda

Gut 2004 53: 1001-1009
doi: 10.1136/gut.2003.027516

Updated information and services can be found at:
http://gut.bmj.com/content/53/7/1001

These include:

References

This article cites 53 articles, 16 of which you can access for free at:
http://gut.bmj.com/content/53/7/1001#BIBL

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

- Cirrhosis (331)
- Hepatic cancer (474)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/